KRAS and pancreatic neoplasm: Our results provide proof-of-concept on the feasibility of non-autologous exosomes to act as nanocarriers for encapsulating and delivering CRISPR/Cas9 plasmid DNA to inhibit mutant Kras-dependent pancreatic cancer cell proliferation in vitro and tumor growth in vivo.